Antiplatelet agents.
Cattaneo
Marco
M
Ospedale San Paolo, University of Milano, Milano, Italy.
D001241:Aspirin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D015195:Drug Design; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D015201:Meta-Analysis as Topic; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000737:chemistry; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011725:Pyridines; C446540:thienopyridine; D000077144:Clopidogrel; C102148:nitroaspirin; D013988:Ticlopidine; D001241:Aspirin